

# MEDICAMENT

## MEDICAL MARIJUANA RESEARCH NEWSLETTER



WINTER 2025

### WELCOME TO MEDICAMENT,

the Consortium for Medical  
Marijuana Clinical Outcomes  
Research's quarterly newsletter.

The Consortium, founded by  
the State of Florida, conducts,  
disseminates, and supports  
research on the use and effects  
of medical marijuana on patient  
outcomes.

*In the Winter 2025 issue of  
MEDICAMENT:*

- FL House Presentation
- 2026 Grants Program Request for Proposals
- CCORC 2026 Save the Date
- Welcome New Consortium Board Members
- Clinical Core Updates
- Evidence & Research Updates
- Journal Corner
- Get Involved in Research



Consortium for  
Medical Marijuana  
Clinical Outcomes Research

To learn more about the  
Consortium and our programs,  
visit us at [mmjoutcomes.org](http://mmjoutcomes.org).

### CONSORTIUM DIRECTOR PRESENTS REPORT TO FLORIDA HOUSE OF REPRESENTATIVES

Presentation provided to Florida Health  
Professions and Programs Subcommittee



On December 9, 2025, Consortium Director Almut Winterstein, RPh, PhD, FISPE, provided a report on Consortium activities to the Health Professions and Programs Subcommittee of the Florida House of Representatives.

The presentation included an overview of the Consortium's research programs and shared updates on data regarding qualifying medical conditions, pediatric and young adult patient demographics, medical marijuana use among pregnant women, and cannabis use disorder. An archived recording of the presentation is available at the link below.

**Note:** Dr. Winterstein's presentation begins at 40:10

**WATCH THE PRESENTATION HERE**

# 2026 RESEARCH GRANTS PROGRAM

Required Letter of Intent Submissions Open! Deadline: February 4, 2026




The banner features the Consortium for Medical Marijuana Clinical Outcomes Research logo (a stylized green leaf with a molecular structure) and the text "Consortium for Medical Marijuana Clinical Outcomes Research". Below this, the text "2026 REQUEST FOR PROPOSALS" is prominently displayed in large white letters. To the right of the text is a photograph of a female scientist in a lab coat and safety glasses looking through a microscope.

The Consortium for Medical Marijuana Clinical Outcomes Research (Consortium) provides awards to support clinical and translational research related to Medical Marijuana (MMJ) to investigators within member institutions.

Research proposals focused on the clinical outcomes of MMJ use, effect of MMJ use in reducing opioid dependence, routes of administration, interactions of MMJ with other drugs/medications, public health outcomes of cannabis laws and regulations, evaluating components of MMJ/cannabis, and mitigation of the risks of cannabis use are encouraged.

The research grant award mechanism will consider fully developed research studies that generate novel evidence, as well as studies intended to facilitate the collection and/or analysis of preliminary data that will support future extramural funding applications.



**LETTER OF INTENT  
DEADLINE  
FEB 4<sup>TH</sup>, 2026**

The Consortium for Medical Marijuana Clinical Outcomes Research has now announced the Request for Proposals (RFP) for the 2026 Research Grants Program.

Researchers interested in applying to the 2026 Research Grants Program must complete the required online [Letter of Intent \(LOI\) Submission Form](#) by 11:59 PM EST, February 4, 2026.

**LEARN MORE ABOUT THE 2026 RFP**

## CCORC 2026 SAVE THE DATE



## WELCOME NEW CONSORTIUM BOARD MEMBERS

The Consortium welcomes two new board members, Nicole Ennis, PhD, of Florida State University, and Candice Sareli, MD, of Nova Southeastern University. We also extend our appreciation to outgoing board members, Eric Holmes, PhD, of Florida State University, and Ken Dawson-Scully, PhD, of Nova Southeastern University, for their years of service.



**Nicole Ennis, PhD**, is an Associate Professor and Vice Chair in the Department of Behavioral Sciences and Social Medicine in the College of Medicine at Florida State University. Guided by a dissemination and implementation science framework, the goal of Dr. Ennis' program of research is to improve patient care through evidence-based behavioral interventions. Since medical marijuana became legal in Florida in 2017, Dr. Ennis and her collaborators have been at the forefront of studying its effects on driving performance and related public health outcomes.



**Candice Sareli, MD**, is Vice President for Human Research and Associate Dean for Research in the Dr. Kiran C. Patel College of Allopathic Medicine (NSU MD). She previously served as the vice president and chief medical research officer at the Memorial Healthcare System (MHS). Previously, Dr. Sareli led a traumatic brain injury study funded by the US Department of Defense and led MHS's COVID-19 research efforts allowing Memorial patients to be the first in Florida to receive Remdesivir. She currently supports clinical trials across all eight colleges at NSU.

## CLINICAL CORE UPDATES

### Consortium Leadership Elected as a Board Member for the Research Society of Marijuana

Consortium Assistant Director of the Clinical Core, Dr. Yan Wang, was recently elected as one of the new board members for the Research Society on Marijuana (RSMj) with a 3-year term starting on January 2026.

### Access the Medical Marijuana and Me (M<sup>3</sup>) Study Data


Researchers from Consortium-member institutions have the opportunity to access data from a cohort of medical marijuana patients in the Medical Marijuana & Me (M<sup>3</sup>) Study. This includes:

- **Cross-sectional survey data:** The data summarize information on utilization patterns and health outcomes from 632 current MMJ users.
- **Longitudinal survey data:** The data summarize information on utilization patterns and health outcomes from 602 new MMJ users. Survey data were collected at baseline before they initiated MMJ, 3 months, and 9 months.

Explore the current M<sup>3</sup> data and resources on our website at [mmjoutcomes.org/m3study](http://mmjoutcomes.org/m3study).

## EVIDENCE AND RESEARCH ANNOUNCEMENTS

New publication from Consortium-affiliated researchers: Cannabinoids for anxiety and sleep disturbances




A scoping review was conducted to synthesize current evidence on the use of cannabinoids for anxiety and sleep disturbances, conditions that frequently co-occur and may share underlying physiological mechanisms such as cortisol dysregulation and impaired executive functioning. This review systematically searched seven major databases and screened studies using PRISMA guidelines, ultimately identifying 29 eligible randomized trials, observational studies, and case series.

Across these studies, cannabinoids, most notably cannabidiol (CBD), showed potential in reducing anxiety symptoms and improving sleep, with about 45% of studies reporting positive effects on both. However, considerable heterogeneity in study design, cannabinoid formulation, and dosing regimens limits confidence in these findings. Overall, while cannabinoids appear promising, more rigorous research with consistent methodologies and clear dose-response evaluations is needed to guide clinical practice.

[Read the full article here >](#)

## JOURNAL CORNER

Updates from Karger, publisher of the Consortium's official journal



*Medical Cannabis and Cannabinoids* is the official journal of the Consortium, offering an international forum to investigate cannabis safety and effectiveness when used for medical purposes. This series in the newsletter, Journal Corner, provides updates, information and resources from the journal publisher, Karger.

Medical Cannabis and Cannabinoids is pleased to announce three new Associate Editors to the journal's board:

**Joseph Tam**, Full Professor, Head, Obesity and Metabolism Laboratory; and Director of the Multidisciplinary Center on Cannabinoid Research; The Hebrew University of Jerusalem, Israel

**Rachel Tomko**, Associate Professor, Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston (CCORC 2025 Keynote Speaker)

**Sara Jane Ward**, Associate Professor, Neural Sciences, Center for Substance Abuse Research, Temple University, Philadelphia (CCORC 2025 Keynote Speaker)

### Medical Cannabis and Cannabinoids at a Glance

- Official journal of the Consortium for Medical Marijuana Clinical Outcomes Research
- Consortium members are eligible for an **article processing charge (APC) discount of 50%** on accepted articles
- Open Access
- Indexed in PMC, DOAJ, Scopus
- CiteScore: 4.4

For more information or questions about *Medical Cannabis and Cannabinoids*, visit the [journal website](#) or contact:

Alan Tootle, Publication Manager,  
[a.tootle@karger.com](mailto:a.tootle@karger.com)

## GET INVOLVED IN RESEARCH

CARMMA: Changing the way we collaborate across the state of Florida

The Consortium invites anyone interested in engaging in medical marijuana research to [register in CARMMA](#) to find collaborators.

The [Connect and Advance Research for Medical Marijuana Analysis \(CARMMA\) Database](#) is accessible to researchers, physicians, and industry collaborators.

We believe collaborations bring research advancements. The CARMMA Database connects researchers, clinicians, and industry to foster medical marijuana research.

**JOIN THE CARMMA DATABASE**



# Happy Holidays

Have news or feedback to share?  
Let us know!

Share your Consortium-related research and news through our [submission form](#).

Share your comments on our newsletter through our [feedback form](#).

Don't want to miss any MEDICAMENT issues?

Share your contact information through our [newsletter sign-up form](#).

[Read previous MEDICAMENT issues on our website](#).

